Compare Stocks: IDYA, EXEL, BMRN, and ARWR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$87.11 -0.4%	$82.84	$20.44 ▼ $95.49	$12.32B	1.27	1.35 million shs	1.09 million shs
BMRN BioMarin Pharmaceutical	$66.70 -1.4%	$60.67	$49.26 ▼ $70.98	$13.10B	0.24	2.33 million shs	1.59 million shs
EXEL Exelixis	$54.08 +0.7%	$54.26	$33.76 ▼ $57.57	$13.30B	0.44	2.75 million shs	1.95 million shs
IDYA IDEAYA Biosciences	$39.67 +1.4%	$36.14	$23.23 ▼ $40.58	$3.44B	-0.1	746,786 shs	860,570 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	-0.41%	+0.54%	-1.79%	+16.22%	+331.24%
BMRN BioMarin Pharmaceutical	-1.45%	-0.98%	+14.21%	+23.31%	+15.08%
EXEL Exelixis	+0.73%	+5.54%	-1.64%	+7.84%	+42.84%
IDYA IDEAYA Biosciences	+1.43%	+9.28%	+13.34%	+36.32%	+63.12%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$87.11 -0.4%	$82.84	$20.44 ▼ $95.49	$12.32B	1.27	1.35 million shs	1.09 million shs
BMRN BioMarin Pharmaceutical	$66.70 -1.4%	$60.67	$49.26 ▼ $70.98	$13.10B	0.24	2.33 million shs	1.59 million shs
EXEL Exelixis	$54.08 +0.7%	$54.26	$33.76 ▼ $57.57	$13.30B	0.44	2.75 million shs	1.95 million shs
IDYA IDEAYA Biosciences	$39.67 +1.4%	$36.14	$23.23 ▼ $40.58	$3.44B	-0.1	746,786 shs	860,570 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	-0.41%	+0.54%	-1.79%	+16.22%	+331.24%
BMRN BioMarin Pharmaceutical	-1.45%	-0.98%	+14.21%	+23.31%	+15.08%
EXEL Exelixis	+0.73%	+5.54%	-1.64%	+7.84%	+42.84%
IDYA IDEAYA Biosciences	+1.43%	+9.28%	+13.34%	+36.32%	+63.12%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.62	Moderate Buy	$97.33	11.74% Upside
BMRN BioMarin Pharmaceutical	2.75	Moderate Buy	$88.83	33.17% Upside
EXEL Exelixis	2.30	Hold	$50.07	-7.42% Downside
IDYA IDEAYA Biosciences	2.81	Moderate Buy	$50.13	26.35% Upside

Current Analyst Ratings Breakdown

Latest IDYA, EXEL, BMRN, and ARWR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2026	BMRN BioMarin Pharmaceutical	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$98.00
8/18/2026	EXEL Exelixis	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$54.00
8/18/2026	BMRN BioMarin Pharmaceutical	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/18/2026	BMRN BioMarin Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$60.00 ➝ $59.00
8/18/2026	EXEL Exelixis	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$54.00
8/17/2026	ARWR Arrowhead Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/17/2026	BMRN BioMarin Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$82.00 ➝ $88.00
8/17/2026	BMRN BioMarin Pharmaceutical	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$105.00 ➝ $111.00
8/11/2026	BMRN BioMarin Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D)
8/11/2026	EXEL Exelixis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B) ➝ Buy (A-)
8/10/2026	BMRN BioMarin Pharmaceutical	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$111.00 ➝ $114.00

(Data available from 8/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$669.50M	18.33	$0.12 per share	732.58	$3.31 per share	26.32
BMRN BioMarin Pharmaceutical	$3.22B	4.01	$2.81 per share	23.72	$32.66 per share	2.04
EXEL Exelixis	$2.32B	5.78	$3.05 per share	17.74	$7.44 per share	7.27
IDYA IDEAYA Biosciences	$218.71M	15.94	N/A	N/A	$13.65 per share	2.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$1.63M	-$2.25	N/A	N/A	N/A	-47.79%	-60.06%	-17.37%	N/A
BMRN BioMarin Pharmaceutical	$348.90M	$0.37	180.27	12.24	0.48	2.14%	5.32%	3.69%	10/26/2026 (Estimated)
EXEL Exelixis	$782.57M	$3.18	17.01	14.54	1.60	35.33%	42.17%	31.76%	11/3/2026 (Estimated)
IDYA IDEAYA Biosciences	-$113.70M	-$1.94	N/A	N/A	N/A	-75.93%	-16.73%	-15.34%	11/3/2026 (Estimated)

Latest IDYA, EXEL, BMRN, and ARWR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	BMRN BioMarin Pharmaceutical	$0.95	$1.20	+$0.25	$0.23	$932.03 million	$989.71 million
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	$0.91	+$0.0570	$0.8438	$636.40 million	$628.69 million
8/4/2026	Q3 2026	ARWR Arrowhead Pharmaceuticals	-$1.23	-$1.36	-$0.13	-$1.36	$44.17 million	$75.25 million
8/4/2026	Q2 2026	IDYA IDEAYA Biosciences	-$1.06	-$1.22	-$0.16	-$1.22	$8.02 million	$8.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	1.77	5.90	5.90
BMRN BioMarin Pharmaceutical	0.56	2.39	1.32
EXEL Exelixis	N/A	3.46	3.38
IDYA IDEAYA Biosciences	N/A	10.45	10.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
BMRN BioMarin Pharmaceutical	98.71%
EXEL Exelixis	85.27%
IDYA IDEAYA Biosciences	98.29%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	3.60%
BMRN BioMarin Pharmaceutical	0.68%
EXEL Exelixis	2.60%
IDYA IDEAYA Biosciences	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	140.86 million	135.79 million	Optionable
BMRN BioMarin Pharmaceutical	3,221	193.57 million	192.26 million	Optionable
EXEL Exelixis	1,077	247.78 million	241.34 million	Optionable
IDYA IDEAYA Biosciences	80	87.86 million	83.73 million	Optionable

IDYA, EXEL, BMRN, and ARWR Headlines

Recent News About These Companies

Great Lakes Advisors LLC Makes New Investment in IDEAYA Biosciences, Inc. $IDYA

August 21 at 4:01 AM | marketbeat.com

Ideaya Biosciences, Genentech Partner for Pancreatic Cancer Trial

August 19 at 12:27 PM | finance.yahoo.com

IDEAYA Biosciences, Inc.: IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer

August 19 at 7:16 AM | finanznachrichten.de

IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer

August 19 at 6:00 AM | prnewswire.com

Bank of America Corp DE Has $31.39 Million Stake in IDEAYA Biosciences, Inc. $IDYA

August 16, 2026 | marketbeat.com

Walleye Capital LLC Buys Shares of 386,183 IDEAYA Biosciences, Inc. $IDYA

August 15, 2026 | marketbeat.com

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Average Recommendation of "Moderate Buy" by Brokerages

August 15, 2026 | americanbankingnews.com

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Rating of "Moderate Buy" from Brokerages

August 15, 2026 | marketbeat.com

IDEAYA Biosciences (NASDAQ:IDYA) Rating Lowered to "Sell" at Wall Street Zen

August 15, 2026 | marketbeat.com

LifeSci Capital Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)

August 12, 2026 | theglobeandmail.com

Analysts Offer Insights on Healthcare Companies: Icon (ICLR) and IDEAYA Biosciences (IDYA)

August 8, 2026 | theglobeandmail.com

Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA) and TransMedics Group (TMDX)

August 6, 2026 | theglobeandmail.com

The Bull Case For IDEAYA Biosciences (IDYA) Could Change Following Wider Loss And New Roche Partnership

August 6, 2026 | finance.yahoo.com

IDEAYA Biosciences (NASDAQ:IDYA) Given New $59.00 Price Target at Truist Financial

August 5, 2026 | marketbeat.com

IDEAYA Biosciences Q2 Loss Widens From Q1, Revenue Rises

August 4, 2026 | finance.yahoo.com

IDEAYA Biosciences (NASDAQ:IDYA) Releases Quarterly Earnings Results, Misses Estimates By $0.16 EPS

August 4, 2026 | marketbeat.com

IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

August 4, 2026 | prnewswire.com

IDEAYA Biosciences (IDYA) Expected to Post Earnings on Monday

August 3, 2026 | marketbeat.com

Dimensional Fund Advisors LP Increases Position in IDEAYA Biosciences, Inc. $IDYA

August 3, 2026 | marketbeat.com

Seven Fleet Capital Management LP Buys New Position in IDEAYA Biosciences, Inc. $IDYA

August 2, 2026 | marketbeat.com

Ideaya Biosciences Inc (IDYA)

July 31, 2026 | fr.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDYA, EXEL, BMRN, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$87.11 -0.36 (-0.41%)

As of 08/21/2026 04:00 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

BioMarin Pharmaceutical NASDAQ:BMRN

$66.70 -0.98 (-1.45%)

As of 08/21/2026 04:00 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Exelixis NASDAQ:EXEL

$54.08 +0.39 (+0.73%)

As of 08/21/2026 04:00 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

IDEAYA Biosciences NASDAQ:IDYA

$39.67 +0.56 (+1.43%)

As of 08/21/2026 04:00 PM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IDYA, EXEL, BMRN, and ARWR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IDYA, EXEL, BMRN, and ARWR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IDYA, EXEL, BMRN, and ARWR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDYA, EXEL, BMRN, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

BioMarin Pharmaceutical NASDAQ:BMRN

Exelixis NASDAQ:EXEL

IDEAYA Biosciences NASDAQ:IDYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IDYA, EXEL, BMRN, and ARWR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IDYA, EXEL, BMRN, and ARWR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IDYA, EXEL, BMRN, and ARWR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDYA, EXEL, BMRN, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

BioMarin Pharmaceutical NASDAQ:BMRN

Exelixis NASDAQ:EXEL

IDEAYA Biosciences NASDAQ:IDYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools